Ticker

Analyst Price Targets — CCCC

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
February 26, 2026 5:14 pmEtzer DaroutBarclays$7.00$2.81StreetInsider C4 Therapeutics (CCCC) PT Raised to $7 at Barclays
December 17, 2025 10:54 amBarclays$5.00$2.26TheFly C4 Therapeutics price target lowered to $5 from $10 at Barclays
September 23, 2025 10:14 amDerek ArchilaWells Fargo$10.00$2.80TheFly C4 Therapeutics price target raised to $10 from $5 at Wells Fargo
September 22, 2025 11:14 amEtzer DaroutBarclays$10.00$3.16TheFly C4 Therapeutics price target raised to $10 from $8 at Barclays
September 16, 2025 8:16 pmBarclays$8.00$3.41TheFly C4 Therapeutics initiated with an Overweight at Barclays
September 15, 2025 10:23 amSudan LoganathanStephens$6.00$3.57TheFly C4 Therapeutics upgraded to Overweight from Equal Weight at Stephens
December 19, 2024 10:39 amDerek ArchilaWells Fargo$12.00$4.31TheFly C4 Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
September 19, 2024 11:45 amEtzer DaroutBMO Capital$20.00$6.87StreetInsider BMO Capital Reiterates Outperform Rating on C4 Therapeutics (CCCC)
January 3, 2023 9:02 amWells Fargo$9.00$6.31Benzinga Wells Fargo Maintains Equal-Weight on C4 Therapeutics, Lowers Price Target to $9
April 28, 2022 6:20 amCredit Suisse$10.00$8.85Benzinga Credit Suisse Initiates Coverage On C4 Therapeutics with Underperform Rating, Announces Price Target of $10

Latest News for CCCC

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for CCCC.

No House trades found for CCCC.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top